Zymeworks price target raised to $10 from $8 at H.C. Wainwright

H.C. Wainwright analyst Robert Burns raised the firm’s price target on Zymeworks to $10 from $8 and keeps a Neutral rating on the shares following the Q4 report. The analyst considers the zanidatamab data very positive when benchmarked against KEYNOTE-811.